Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Stem Cell Transplantation for Hematological Malignancies

Phase 2

Terminated

Conditions: Leukemia, Lymphocytic, Acute
AML
MDS

Interventions: Procedure: Stem Cell Transplant
Drug: Busulfan
Drug: Cyclophosphamide
Drug: Melphalan
Drug: G-CSF
Drug: ATG

First Posted Date: 2005-09-15

Last Posted Date: 2017-12-05

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 11

Registration Number: NCT00176839

Locations: 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States

CINJALL: Treatment for Children With Acute Lymphocytic Leukemia

Phase 2

Completed

Conditions: Acute Lymphocytic Leukemia

Interventions: Drug: L-asparaginase
Drug: aminopterin
Drug: daunomycin
Drug: dexamethasone
Drug: cyclophosphamide
Drug: 6-mercaptopurine
Drug: cytarabine
Drug: methotrexate
Drug: vincristine
Drug: Triple Intrathecal Therapy (MTX, Cytarabine, Hydrocortisone)
Drug: Leucovorin
Drug: 6-thioguanine

First Posted Date: 2005-09-15

Last Posted Date: 2014-06-09

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 60

Registration Number: NCT00176462

Locations: 🇺🇸
Jersey Shore University Medical Center, Neptune, New Jersey, United States
🇺🇸
Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

Phase II Metronomic Dosing, Etoposide, Cyclophosphamide, D0 Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Etoposide
Drug: Cyclophosphamide

First Posted Date: 2005-09-15

Last Posted Date: 2014-05-20

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 15

Registration Number: NCT00176605

Locations: 🇺🇸
UMDNJ/Robert Wood Johnson Medical School, Newark, New Jersey, United States
🇺🇸
Robert Wood Johnson University Hospital/CINJ at Hamilton, Hamilton, New Jersey, United States
🇺🇸
Morristown Memorial Hospital, Morristown, New Jersey, United States

and more 4 locations

ACVBP Followed by ASCT in Patients With BCL-2 Positive Diffuse Large B-Cell Lymphoma

Phase 2

Completed

Conditions: Lymphoma, Large-Cell, Diffuse

First Posted Date: 2005-09-15

Last Posted Date: 2007-07-13

Lead Sponsor: Lymphoma Study Association

Target Recruit Count: 300

Registration Number: NCT00169130

Locations: 🇫🇷
Hôpital Saint Louis, Paris, France
🇧🇪
Service d'Hematologie, Mont-Godinne, Belgium
🇫🇷
Hôpital Henri Mondor, Creteil, France

and more 2 locations

A Phase II Study of Rituximab Combined With CHOP in T-cell Angio-immunoblastic Lymphoma

Phase 2

Completed

Conditions: Untreated T-cell Angioimmunoblastic Lymphoma

Interventions: Drug: Rituximab
Drug: Prednisone
Drug: Doxorubicine
Drug: Cyclophosphamide
Drug: Vincristine

First Posted Date: 2005-09-15

Last Posted Date: 2017-03-13

Lead Sponsor: Lymphoma Study Association

Target Recruit Count: 27

Registration Number: NCT00169156

Locations: 🇫🇷
Hôpital Henri Mondor, Créteil, France
🇫🇷
Service d'Hématologie - Centre Hospitalier Lyon-Sud, Pierre-Bénite cedex, France
🇫🇷
Centre Henri Becquerel, Rouen, France

and more 1 locations

A Trial of Thalidomide, Celecoxib, Etoposide and Cyclophosphamide in Patients With Relapsed or Progressive Cancer

Phase 2

Completed

Conditions: Neoplasms

First Posted Date: 2005-09-14

Last Posted Date: 2011-07-07

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 20

Registration Number: NCT00165451

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Intensive Chemo-Radiotherapy With Peripheral Blood Progenitor Cell Rescue for Children With Advanced Neuroblastoma and Sarcomas

Phase 2

Completed

Conditions: Neuroblastoma
Ewings Sarcoma
Non-rhabdomyosarcoma Soft Tissue Sarcoma

First Posted Date: 2005-09-14

Last Posted Date: 2009-11-01

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 20

Registration Number: NCT00165139

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Preoperative Herceptin and Navelbine for Breast Cancer

Phase 2

Completed

Conditions: Stage III Breast Cancer
Breast Cancer
Stage II Breast Cancer

Interventions: Drug: Herceptin
Drug: Navelbine
Drug: Doxorubicin
Drug: Cyclophosphamide
Drug: Paclitaxel

First Posted Date: 2005-09-08

Last Posted Date: 2019-01-15

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 49

Registration Number: NCT00148681

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Center, Boston, Massachusetts, United States

Preoperative Treatment of Breast Cancer With Two Different Sequential Treatment Regimens

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: pemetrexed
Drug: cyclophosphamide
Drug: doxorubicin
Drug: docetaxel

First Posted Date: 2005-09-08

Last Posted Date: 2012-03-21

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 257

Registration Number: NCT00149214

Locations: 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Valencia, Spain

Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer
Stage I Breast Cancer
Stage II Breast Cancer

First Posted Date: 2005-09-07

Last Posted Date: 2023-08-02

Lead Sponsor: Harold J. Burstein, MD, PhD

Target Recruit Count: 135

Registration Number: NCT00146562

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 3 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy